Last reviewed · How we verify
Tick-Borne Encephalitis vaccine
At a glance
| Generic name | Tick-Borne Encephalitis vaccine |
|---|---|
| Sponsor | Novartis |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine (PHASE4)
- Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
- Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children (PHASE3)
- Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older (PHASE3)
- Primary TBE Vaccination for the Elderly (PHASE4)
- Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients (PHASE2)
- Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules (PHASE4)
- New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tick-Borne Encephalitis vaccine CI brief — competitive landscape report
- Tick-Borne Encephalitis vaccine updates RSS · CI watch RSS
- Novartis portfolio CI